Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 109

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 109
---
 for similar
assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through
market corroboration, for substantially the full term of the financial instrument.

Level 3 - Inputs are unobservable inputs based
on our assumptions.

New Accounting Pronouncements

The Company considered the applicability and impact
of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance
sheets or statement of operations and comprehensive loss.

<div align='center'>59

MANAGEMENT</div>

Executive Officers

The following table sets forth certain information regarding our executive
officers and directors as of the date of this prospectus.

| Name                      |     | Age |     | Director Since |     | Position                                        |
| Cuong Do                  |     |  59 |     |           2016 |     | Chief Executive Officer, President and Director |
| Joanne Wendy Kim          |     |  70 |     |             -- |     | Chief Financial Officer                         |
| Joseph M. Palumbo, MD     |     |  65 |     |             -- |     | Chief Medical Officer                           |
| Jim Lang                  |     |  60 |     |           2016 |     | Chairman of the Board                           |
| Amy S. Chappell, MD, FAAN |     |  74 |     |           2025 |     | Director                                        |
| Kameel D. Farag           |     |  47 |     |           2025 |     | Director                                        |
| Sigmund Rogich            |     |  81 |     |           2020 |     | Director                                        |
| Michael Sherman           |     |  66 |     |           2017 |     | Director                                        |

Mr. Cuong Do has served on the Company’s
Board of Directors since 2016 and was appointed the Company’s Chief Executive Officer (“CEO”) and President in 2021.
He previously served as President, Global Strategy Group at Samsung from 2015 to 2020. Mr. Do helped set the strategic direction for
Samsung’s diverse business portfolio. Prior to that, he was the Chief Strategy Officer for Merck from 2011 to 2014, Tyco Electronics
from 2009 to 2011, and Lenovo from 2007 to 2009. Mr. Do is a former senior partner at McKinsey & Company, where he spent